Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Severe COVID-19 rare in PrEP-treated SARDs patients
Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024
Adalimumab concentrations negatively linked to inflammatory markers in RA
A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.
Adalimumab concentrations negatively linked to inflammatory markers in RA
08 Mar 2024
High CRP level tied to earlier death in ILD
Increased levels of serum C-reactive protein (CRP) may contribute to shorter survival in patients with idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), or systemic sclerosis (SSc)-associated ILD at 5 years.
High CRP level tied to earlier death in ILD
07 Mar 2024
Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
The use of abatacept in adults at high risk of rheumatoid arthritis helps protect against disease onset, as shown in the phase IIB APIPPRA study.
Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
23 Feb 2024
Serious infections prevalent in RTX-treated patients with SLE
A recent study has reported the prevalence of serious infection (SI) among patients with systemic lupus erythematosus (SLE) following treatment with rituximab (RTX).
Serious infections prevalent in RTX-treated patients with SLE
13 Feb 2024
Is BASDAI a responsive instrument in PsA?
Use of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as an instrument in psoriatic arthritis (PsA) demonstrates “reasonable” responsiveness but falls short of distinguishing peripheral PsA from axial (ax)PsA, according to a recent study.